Skip to main content
. 2003 Mar;23(6):1874–1884. doi: 10.1128/MCB.23.6.1874-1884.2003

FIG. 5.

FIG. 5.

FIG. 5.

FIG. 5.

SF2/ASF and SC35 differ in their enhancement of N1. (A) Coomassie staining of purified proteins used in the experiment and separated in an SDS polyacrylamide gel. (B) In vitro splicing reactions in the presence of added SR proteins. Splicing of BS303 (lanes 1 to 5 and 11 to 15) and BS304 (lanes 6 to 10 and 16 to 20) was done in the presence of 100 μg of Weri-1 nuclear extract. Lanes 2 to 5 and 7 to 10 both contain 50, 100, 200, and 400 ng of SF2/ASF, respectively. Lanes 12 to 15 and 17 to 20 both contain 50, 100, 200, and 400 ng of SC35, respectively. Lanes 1, 6, 11, and 16 contain Weri-1 extract without any additional factors. Quantification of the products is shown below the gel. (C) La does not affect splicing of BS303 or BS304. Splicing of BS303 and BS304 was done in the presence of 100 μg of Weri-1 nuclear extract. Lanes 2 to 5 and 7 to 10 both contain 0.200, 0.400, 0.800, and 2 μg of La, respectively. Lanes 1 and 6 contain Weri-1 extract without any additional factors.